詹姆斯·A·兰德青年研究者奖:全膝关节置换术中静脉地塞米松的最安全有效剂量是什么?一项多中心随机对照试验
这项多中心、双盲、前瞻性随机对照试验将404例初次全膝关节置换术患者随机分为术中静脉注射地塞米松4mg(n=138)、8mg(n=137)或16mg(n=129)三组。16mg组在术后第1天阿片类药物消耗量更少、呕吐次数更少、静息疼痛评分更低,但术后第1天血糖最高。24小时后各组阿片消耗、睡眠和恶心等结局相当。
要点
- 16mg组术后第1天MME消耗为27,低于4mg组的38和8mg组的37(P=0.047)。
- 16mg组呕吐次数更少(P=0.02),24小时、48小时和一周静息疼痛评分更低。
- 16mg组术后第1天血糖最高(P<0.001),但住院时间、睡眠时长和90天并发症率组间无差异。
核心结论
- 全膝关节置换术中静脉注射高剂量(16mg)地塞米松可减少术后第一天的阿片类药物消耗、疼痛和呕吐。
- 超过24小时后,所有剂量的阿片消耗、睡眠和恶心等结局相当。
研究设计与样本
- 多中心、双盲、前瞻性随机对照试验,纳入404例接受住院初次全膝关节置换术的患者,随机分入4mg组(n=138)、8mg组(n=137)或16mg组(n=129),术中静脉给药。
- 所有中心采用相同的围手术期多模式方案,术后7天收集阿片消耗量(以吗啡毫克当量MME计)、疼痛评分、恶心评分、呕吐次数和睡眠时长,术后第1天(POD1)测量血糖水平。
- 平均年龄68岁,平均体质指数33,62%为女性;连续数据采用独立样本t检验,离散数据采用卡方检验和Fisher精确检验;各组人口学特征可比,提示随机化成功。
主要发现
- 16mg组术后第1天MME消耗为27,4mg组为38,8mg组为37(P=0.047);16mg组呕吐次数更少(P=0.02)。
- 16mg组在24小时、48小时和一周的静息疼痛评分更低。
- 术后48小时内累积阿片消耗量(P=0.24)、一周累积阿片消耗量(P=0.43)以及任何时间点的活动疼痛组间无差异。
- 术后第1天血糖在16mg组最高(P<0.001)。
- 住院时间、睡眠小时数和90天并发症率组间无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this multicenter, double-blinded, prospective, randomized controlled trial was to determine the safest and most effective dose of intravenous (IV) dexamethasone administered during primary total knee arthroplasty (TKA). METHODS: There were 404 patients undergoing inpatient primary TKA randomized across 11 centers to receive four (n = 138), eight (n = 137), or 16 mg (n = 129) of IV dexamethasone intraoperatively. All sites utilized the same perioperative multimodal protocol. Opioid consumption measured in morphine milligram equivalents (MME), pain scores, nausea scores, vomiting episodes, and sleep duration was collected for 7 days postoperatively. Glucose levels were measured on postoperative day 1 (POD1). The mean age was 68 years, the mean body mass index was 33, and 62% were women. Independent sample t-tests were used for continuous data, and Chi-square and Fisher's exact tests were used for discrete data. Demographic characteristics were comparable between groups, suggesting successful randomization. RESULTS: Patients who received 16 mg IV dexamethasone consumed less MME on POD1 (38 versus 37 versus 27 MME; P = 0.047) and had fewer vomiting episodes (P = 0.02). Patients who received 16 mg also had lower pain scores at rest at 24 hours, 48 hours, and one week. There were no differences in cumulative opioid consumption within the first 48 hours (P = 0.24), one week (P = 0.43), or pain with activity at any time point. The POD1 glucose was highest in patients who received 16 mg (P < 0.001). There were no differences in length of stay, hours slept, or 90-day complication rates between groups. CONCLUSIONS: High-dose (16 mg) IV dexamethasone in TKA reduces opioid consumption, pain, and vomiting on the first day after surgery. Outcomes, including opioid consumption, sleep, and nausea, are comparable beyond 24 hours for all doses. LEVEL OF EVIDENCE: I. Prospective randomized controlled trial.
引用
- Hannon CP, DeBenedetti A, Barrack RL, et al. The James A. Rand Young Investigator's Award: What Is the Safest and Most Effective Dose of Intravenous Dexamethasone in Total Knee Arthroplasty? A Multicenter Randomized Controlled Trial. J Arthroplasty. 2025. PMID: 40339943. doi:10.1016/j.arth.2025.04.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。